hodgkin's lymphoma | Welcome to our web site!

Welcome to our web site!

The competence network Malignant Lymphoma e.v. wants to inform patients, doctors and scientists comprehensively about lymphoma and the work of the Lymphoma research groups. Do you like our information portal? Do you miss anything? What can we do to help you better? We are looking forward to your reply! 

Logo membership with link to more information

BVML-LogoAus IVML will BVML-new participation documents: for the "Integrated care of patients with Malignant Lymphoman" (IVML) project coordinated by KML for 10 years, the European Data Protection basic Regulation (EU-DSGVO) has been Changes. As part of these adjustments, the project was renamed to "special care of patients with Malignant Lymphoman" (BVML) on the basis of § 140a GBS v.

Press release on the subject

Michael Pfreundschuh (Becker  "Bredel) Mourning for Michael Pfreundschuh: On March 5, 2018, our founding and longtime board member Prof. Dr. Michael Pfreundschuh died at the age of 68 years. The Director of the Department of Internal Medicine I of the University Hospital in Homburg/Saar and head of the German Study Group high malignant non-Hodgkin lymphoma (DSHNHL) was highly esteemed as an outstanding physician and internationally recognized cancer scientist. Over all these years, the institution of the federal merit has significantly contributed to shaping and shaping the work of the competence network Malignant Lymphoma e.v. (KML). With HMI we lose an inspiring and loyal companion. Our sympathy is with his family, friends and colleagues. The KML board and the staff of the KML office (Photo: Becker & Bredel)

Obituary

Hartmut GoldschmidtHartmut Goldschmidt receives the German Cancer Prize for Clinical Research: On February 22, 2018, Prof. Dr. Hartmut Goldschmidt (Heidelberg) of the German Cancer Society (DKG) was awarded the German Cancer Prize for clinical research Excellent. As head of the GMMG-Study Group, H. Goldschmidt has been involved in the research and therapy optimization of multiple myeloma for more than 25 years and, through the establishment of modern therapy with new active ingredients, has helped to ensure that the average Life expectancy of patients with multiple myeloma could be doubled. (Photo: University Hospital Heidelberg)

Press release of Heidelberg University Hospital

Picture of page 1 of the GCLLSG study map current therapeutic pathways and Study Overview of CLL: On the occasion of its 30th working meeting on 20/21 October 2017 in Schloss Hohenkammer near Munich, the German CLL Study Group (GCLLSG) together with the competence network Malignant lymphoma e.v. (KML) issued a DIN-A4 map of the current treatment paths for patients with chronic lymphocytic leukemia (CLL). Depending on the stage of the disease, the fitness and the risk profile of the patient, it is graphically prepared how patients should be treated in case of first disease (Firstline therapies) or after relapse (relapse therapies) – preferably in the context of GCLLSG studies or a standard recommended by the GCLLSG (update status: 13 October 2017). Treatment centers can request individual copies of the laminated card from the KML. 

Press release on the subject

GCLLSG-map  "Therapy Trails & Study Overview" Research news: New therapy option for follicular lymphoma: In its latest edition, The New England Journal of Medicine reports on the results of an international multicenter study jointly conducted by The German study group low Malignant lymphoma (GLSG) was scientifically coordinated under the direction of Prof. Dr. Wolfgang Hiddemann (Munich) and the English Lymphomstudiengruppe (NCRI) under the direction of Dr. Robert Marcus. In this study, in more than 1,200 patients with untreated follicular lymphomas, the new antibody Obinutuzumab was compared with the previously regarded as the standard antibody Rituximab. The study showed a clear superiority of the new antibody, which reduced the likelihood of a refall by more than one-third. This means that patients with this disease live on average for about three years longer without relapse and thus gain significantly in life and quality of life. 

To the press release of the LMU Munich

KML Training Series 2017 | 2018 with new themes started: The topics of this training series are ' indolent lymphomas ' and ' Hodgkin lymphoma '. From now on, hospitals and clinics can invite a designated KML expert to their home, who will talk about 45 minutes on the topic and answer questions in the ensuing discussion. In the training of indolent lymphomas, the follicular lymphoma, mantle cell lymphoma, or waldenstrom disease can be selected as the main focus.

KML Training Initiative

New release: Flyer on CNS lymphoma: The KML has its information materials for brief information on the topic of CNS lymphoma | Lymphomas of the central nervous system  "extended. The flyer and all other brochures can be ordered from the KML office and downloaded from this website.